Payment overview · 2025
General Payments
$567.10
20 reported records · 11 companies
Healthcare provider profile · identity verified
Steven E. Miller, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW CASTLE, IN · NPI 1134165905
Verified facts
What the public records show
CMS Open Payments records show Steven E. Miller, M.D. received $567.10 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 51.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $291.50 | 51.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.21 | 11.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.58 | 9.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $30.26 | 5.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.16 | 5.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.06 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.73 | 3.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.03 | 3.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.43 | 2.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.61 | 2.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $13.53 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $567.10 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $159.85 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $131.65 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.21 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $58.42 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.58 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.58 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 226 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
189 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
226 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
269 | 61 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1609 | 449 |
| Amlodipine Besylate | Amlodipine Besylate | 839 | 234 |
| Levothyroxine Sodium | Levothyroxine Sodium | 821 | 187 |
| Omeprazole | Omeprazole | 741 | 223 |
| Lisinopril | Lisinopril | 525 | 149 |
| Metoprolol Succinate | Metoprolol Succinate | 483 | 140 |
| Losartan Potassium | Losartan Potassium | 444 | 128 |
| Hydrochlorothiazide | Hydrochlorothiazide | 435 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 383 | 112 |
| Metformin Hcl | Metformin Hcl | 343 | 97 |
| Gabapentin | Gabapentin | 318 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 293 | 93 |
| Tamsulosin Hcl | Tamsulosin Hcl | 286 | 88 |
| Sertraline Hcl | Sertraline Hcl | 270 | 75 |
| Eliquis | Apixaban | 269 | 61 |
| Ezetimibe | Ezetimibe | 259 | 92 |
| Furosemide | Furosemide | 247 | 89 |
| Bupropion Xl | Bupropion Hcl | 240 | 66 |
| Spironolactone | Spironolactone | 238 | 69 |
| Ozempic | Semaglutide | 226 | 43 |
| Metformin Hcl Er | Metformin Hcl | 218 | 67 |
| Trazodone Hcl | Trazodone Hcl | 217 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 216 | 56 |
| Alprazolam | Alprazolam | 213 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 213 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 206 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 203 | 67 |
| Potassium Chloride | Potassium Chloride | 202 | 65 |
| Trulicity | Dulaglutide | 200 | 37 |
| Montelukast Sodium | Montelukast Sodium | 198 | 60 |
| Simvastatin | Simvastatin | 198 | 53 |
| Farxiga | Dapagliflozin Propanediol | 189 | 45 |
| Donepezil Hcl | Donepezil Hcl | 180 | 49 |
| Carvedilol | Carvedilol | 177 | 50 |
| Tramadol Hcl | Tramadol Hcl | 155 | 38 |
| Allopurinol | Allopurinol | 150 | 44 |
| Mounjaro | Tirzepatide | 148 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 144 | 40 |
| Jardiance | Empagliflozin | 142 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 142 | 37 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 140 | 112 |
| Fluoxetine Hcl | Fluoxetine Hcl | 136 | 37 |
| Buspirone Hcl | Buspirone Hcl | 131 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 129 | 27 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 124 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 123 | 33 |
| Meloxicam | Meloxicam | 114 | 34 |
| Valsartan | Valsartan | 111 | 32 |
| Famotidine | Famotidine | 110 | 42 |
| Pregabalin | Pregabalin | 110 | 37 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 98 | 34 |
| Prednisone | Prednisone | 97 | 73 |
| Celecoxib | Celecoxib | 90 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 27 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 86 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 83 | 25 |
| Warfarin Sodium | Warfarin Sodium | 82 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 16 |
| Azithromycin | Azithromycin | 70 | 63 |
| Clonazepam | Clonazepam | 63 | 17 |
| Ondansetron Odt | Ondansetron | 63 | 32 |
| Ramipril | Ramipril | 61 | 17 |
| Finasteride | Finasteride | 60 | 21 |
| Atenolol | Atenolol | 58 | 18 |
| Fenofibrate | Fenofibrate | 58 | 13 |
| Glimepiride | Glimepiride | 54 | 15 |
| Torsemide | Torsemide | 54 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 17 |
| Topiramate | Topiramate | 51 | 13 |
| Mirtazapine | Mirtazapine | 49 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 49 | 17 |
| Rybelsus | Semaglutide | 48 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 47 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 47 | 13 |
| Temazepam | Temazepam | 47 | suppressed |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 43 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 18 |
| Synthroid | Levothyroxine Sodium | 42 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 42 | suppressed |
| Chlorthalidone | Chlorthalidone | 40 | suppressed |
| Lorazepam | Lorazepam | 40 | 11 |
| Nitroglycerin | Nitroglycerin | 40 | 22 |
| Eszopiclone | Eszopiclone | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 17 |
| Meclizine Hcl | Meclizine Hcl | 37 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 36 | 16 |
| Diazepam | Diazepam | 36 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 32 |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 35 | 14 |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 16 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | 11 |
| Cephalexin | Cephalexin | 31 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 31 | 13 |
| Glipizide | Glipizide | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 22 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 22 |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Colchicine | Colchicine | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Magnesium Sulfate | Magnesium Sulfate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Unithroid | Levothyroxine Sodium | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Baclofen | Baclofen | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $567.10 · 20 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, CAPLYTA, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, VRAYLAR, Veozah, WaveWriter Alpha Prime 16, Wegovy, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error